Pharmaceutical, Hart-Scott-Rodino Act

New FTC/DOJ Position Will Require Heightened Regulatory Reporting of Pharma, Biological and Diagnostic Licenses -- October 25,...

by Loeb & Loeb LLP on 10/3/2012

The Federal Trade Commission and Department of Justice recently announced revisions to the Hart-Scott-Rodino (HSR) Act’s premerger notification rules to require enhanced reporting of transactions (including licenses) relating...more

FTC proposes framework for the transfer of patent rights in the pharmaceutical industry

by Saul Ewing LLP on 10/2/2012

The FTC has proposed amendments to the premerger notification Rules to codify prior FTC guidance concerning when a transaction involving the transfer of rights to a patent in the pharmaceutical and medicine manufacturing...more

FTC Seeks Comments on Proposed HSR Rule Amendments Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical...

by Perkins Coie on 9/10/2012

The Federal Trade Commission (“FTC”) recently announced and asked for comments on proposed changes to the premerger notification rules under the Hart-Scott-Rodino Act (“HSR Act”). The proposed rules would require...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

Pharmaceutical › Hart-Scott-Rodino Act

New FTC/DOJ Position Will Require Heightened Regulatory Reporting of Pharma, Biological and Diagnostic Licenses -- October 25,...

FTC proposes framework for the transfer of patent rights in the pharmaceutical industry

FTC Seeks Comments on Proposed HSR Rule Amendments Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical...

FTC Sights Set on Pharma Deals – Calls for Additional Hart-Scott-Rodino Reporting

FTC Flexes Healthcare Regulatory Muscle

Yet Another Turn of the Screw: The FTC Again Targets Pharmaceutical Industry, This Time Through the HSR Act

Expand Your Reach